SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

HP661

Item No. 38927



Formal Name:	5-((5-methyl-4-(4-(4-(2,2,2-trifluoroethoxy)benzyl)piperazine-1-carbonyl)-1H-1,2,3-triazol-1-yl)methyl)-N-(4-(trifluoromethyl)phenyl)picolinamide
MF:	$C_{31}H_{29}F_6N_7O_3$
FW:	661.6
Purity:	≥98%
UV/Vis.:	λ_{max}: 225, 281 nm
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	≥2 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

HP661 is supplied as a crystalline solid. A stock solution may be made by dissolving the HP661 in the solvent of choice, which should be purged with an inert gas. HP661 is soluble in methanol and chloroform.

Description

HP661 is an inhibitor of mitochondrial complex I, also known as NADH dehydrogenase.[1] It is selective for complex I, inhibiting it by 77.6%, over complex III, which it inhibits by 28.1%, and complexes II and IV, which it does not inhibit, at 1 µM. HP661 selectively reduces viability of the human lung cancer cells H460, NCI H441, and trametinib-resistant A549 cells (IC_{50}s = 10.6, 29.7, and 15.1 nM, respectively), which all have high levels of oxidative phosphorylation, over NCI H358 human lung cancer cells (IC_{50} = >10,000 nM), which have low levels of oxidative phosphorylation, and non-cancerous human pancreatic normal epithelial (HPNE) and MRC-5 human fetal lung fibroblast cells (IC_{50}s = >10,000 nM for both). HP661 reduces tumor volume in an H460 mouse xenograft model when administered at a dose of 30 mg/kg twice per day and has an additive effect on trametinib-induced reduction of tumor growth.

Reference

1. He, P., Feng, J., Xia, X., *et al.* Discovery of a potent and oral available complex I OXPHOS inhibitor that abrogates tumor growth and circumvents MEKi resistance. *J. Med. Chem.* **66(9)**, 6047-6069 (2023).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM